From FDA in Brief: The FDA seeks input from consumers and medical professionals on making sure the drug risk information in statements included in direct-to-consumer broadcast advertisements accurately informs consumers. To ensure that the Agency considers your comment, submit either electronic or written information and comments by November 20, 2017.
“The FDA is interested in hearing from stakeholders, including consumers and medical professionals, about the information that should be included in the disclosure of risk information in direct-to-consumer broadcast advertisements for prescription drugs. To facilitate this feedback, the FDA issued a Federal Register notice requesting comments to a public docket. More information on how to submit feedback on the content of risk information in direct-to-consumer broadcast advertisements for prescription drugs and the questions posed can be found in the Federal Register notice.”
